Ogunniyi A D, Folland R L, Briles D E, Hollingshead S K, Paton J C
Molecular Microbiology Unit, Women's and Children's Hospital, North Adelaide, SA 5006, Australia.
Infect Immun. 2000 May;68(5):3028-33. doi: 10.1128/IAI.68.5.3028-3033.2000.
The vaccine potential of a combination of three pneumococcal virulence proteins was evaluated in an active-immunization-intraperitoneal-challenge model in BALB/c mice, using very high challenge doses of Streptococcus pneumoniae. The proteins evaluated were a genetic toxoid derivative of pneumolysin (PdB), pneumococcal surface protein A (PspA), and a 37-kDa metal-binding lipoprotein referred to as PsaA. Mice immunized with individual proteins or combinations thereof were challenged with high doses of virulent type 2 or type 4 pneumococci. The median survival times for mice immunized with combinations of proteins, particularly PdB and PspA, were significantly longer than those for mice immunized with any of the antigens alone. A similar effect was seen in a passive protection model. Thus, combinations of pneumococcal proteins may provide the best non-serotype-dependent protection against S. pneumoniae.
在BALB/c小鼠的主动免疫-腹腔内攻击模型中,使用非常高剂量的肺炎链球菌进行攻击,评估了三种肺炎球菌毒力蛋白组合的疫苗潜力。所评估的蛋白包括肺炎溶血素的基因类毒素衍生物(PdB)、肺炎球菌表面蛋白A(PspA)以及一种称为PsaA的37 kDa金属结合脂蛋白。用单个蛋白或其组合免疫的小鼠接受高剂量的2型或4型强毒肺炎球菌攻击。用蛋白组合免疫的小鼠,特别是PdB和PspA组合免疫的小鼠,其平均存活时间显著长于单独用任何一种抗原免疫的小鼠。在被动保护模型中也观察到了类似的效果。因此,肺炎球菌蛋白组合可能提供针对肺炎链球菌的最佳非血清型依赖性保护。